Full Text:   <297>

CLC number: 

On-line Access: 2022-02-17

Received: 2022-04-22

Revision Accepted: 2022-04-22

Crosschecked: 2022-04-22

Cited: 0

Clicked: 288

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Fu-Qiang Hu

https://orcid.org/0000-0002-9847-134X

Xuan LIU

https://orcid.org/0000-0001-6344-8345

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2022 Vol.23 No.2 P.171-172

http://doi.org/10.1631/jzus.B19e0468


Erratum to: Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment


Author(s):  Xuan LIU, Xueqing ZHOU, Xuwei SHANG, Li WANG, Yi LI, Hong YUAN, Fuqiang HU

Affiliation(s):  College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, China

Corresponding email(s):   hufq@zju.edu.cn

Key Words:  Doxorubicin, Tumor metastasis, Ras-related C3 botulinum toxin substrate 1 (RAC1), Epithelial-mesenchymal transition (EMT), Chitosan micelles, Small interfering RNA (siRNA)


Share this article to: More <<< Previous Article|

Xuan LIU, Xueqing ZHOU, Xuwei SHANG, Li WANG, Yi LI, Hong YUAN, Fuqiang HU. Erratum to: Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment[J]. Journal of Zhejiang University Science B, 2022, 23(2): 171-172.

@article{title="Erratum to: Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment",
author="Xuan LIU, Xueqing ZHOU, Xuwei SHANG, Li WANG, Yi LI, Hong YUAN, Fuqiang HU",
journal="Journal of Zhejiang University Science B",
volume="23",
number="2",
pages="171-172",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B19e0468"
}

%0 Journal Article
%T Erratum to: Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment
%A Xuan LIU
%A Xueqing ZHOU
%A Xuwei SHANG
%A Li WANG
%A Yi LI
%A Hong YUAN
%A Fuqiang HU
%J Journal of Zhejiang University SCIENCE B
%V 23
%N 2
%P 171-172
%@ 1673-1581
%D 2022
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B19e0468

TY - JOUR
T1 - Erratum to: Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment
A1 - Xuan LIU
A1 - Xueqing ZHOU
A1 - Xuwei SHANG
A1 - Li WANG
A1 - Yi LI
A1 - Hong YUAN
A1 - Fuqiang HU
J0 - Journal of Zhejiang University Science B
VL - 23
IS - 2
SP - 171
EP - 172
%@ 1673-1581
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B19e0468


Abstract: 
The online version of the original article can be found at https://doi.org/10.1631/jzus.B1900468The original version of this article (Liu et al., 2020) unfortunately contained some mistakes.1. Figs. 7c and 7d in p.229 were incorrect. The upper left and bottom left pictures in Fig. 7c were accidentally duplicated with the pictures at the same position of Fig. 1a. The upper right and bottom right pictures were mistakenly placed in Fig. 7c. Therefore, the calculation results in Fig. 7d were also mistaken. The correct versions should be as follows:2. Because of the wrong pictures of Fig. 7c, the calculated results of "42.5%" in Abstract, Sections 3.9 and 5 are also mistaken. The correct result should be "45.2%."(1) Lines 10–12 of Abstract in p.218: "CSO-ss-SA/siRNA could effectively transmit siRNA into tumor cells, reducing the expression of RAC1 protein by 38.2% and decreasing the number of tumor-induced invasion cells by 42.5%." was incorrect. The correct version should be "CSO-ss-SA/siRNA could effectively transmit siRNA into tumor cells, reducing the expression of RAC1 protein by 38.2% and decreasing the number of tumor-induced invasion cells by 45.2%."(2) Lines 23–26 of Section 3.9 in p.227: "It was shown that the number of invasive tumor cells induced by DOX was reduced by 42.5% since CSO-ss-SA/siRNA downregulated the expression of RAC1 protein." was incorrect. The correct version should be "It was shown that the number of invasive tumor cells induced by DOX was reduced by 45.2% since CSO-ss-SA/siRNA downregulated the expression of RAC1 protein."(3) Lines 4–8 of Section 5 in p.231: "CSO-ss-SA, as an efficient redox-sensitive carrier for delivering siRNA silencing RAC1 into tumor cells, reduced the expression of RAC1 by 38.2% and decreased DOX-induced tumor invasion cells by 42.5% in vitro." was incorrect. The correct version should be "CSO-ss-SA, as an efficient redox-sensitive carrier for delivering siRNA silencing RAC1 into tumor cells, reduced the expression of RAC1 by 38.2% and decreased DOX-induced tumor invasion cells by 45.2% in vitro."

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]LiuX, ZhouXQ, ShangXW, et al., 2020. Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(3):218-233.http://doi.org/10.1631/jzus.B1900468

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE